WuXi AppTec, a leading global pharmaceutical R&D service platform, saw its A-shares hit the daily upper limit on April 28, while its H-shares surged over 17% at one point. The company reported Q1 net profit growth of 26.68%, beating market expectations.

The strong performance boosted the entire innovative drug sector, with analysts viewing WuXi AppTec as a bellwether for the industry. The company attributed its growth to increasing global pharmaceutical R&D investment and accelerated overseas expansion of Chinese innovative drugs.

Industry experts note that with normalized medical insurance negotiations, faster drug approval processes, and expanding international market access, China’s innovative drug industry is entering a golden development period.